After graduating with a degree in Applied Chemistry Andrew moved into the research sector working for a range of Pharmaceutical companies including Roche, Napp, Parke-Davis and Pfizer. From an early point in his career he began to specialize in new enabling chemical technologies and automation specializing in high throughput synthesis and purification and flow chemistry.
At Pfizer Andrew led the flow chemistry initiative working across research projects and process groups to integrate flow chemistry in Pfizer's workflow. During this time that Andrew undertook an industrial secondment in Prof. Steve Ley's group developing his knowledge in the flow field. After the Pfizer (Sandwich) site closed Andrew took his expertise and ran his own consultancy company developing batch to flow processes, training and working with flow chemistry apparatus manufactures to develop their technology and develop in-house applications. Andrew moved to Syrris in early 2015 first in a technical role to develop flow chemistry applications, moving into Product Management before taking the position as Head of Flow Chemistry Products expanding his role to cover Syrris’ complete flow chemistry portfolio.
Compound Library Generation using Flow Chemistry
Monday, 25 March 2024 at 16:30
Add to Calendar ▼2024-03-25 16:30:002024-03-25 17:30:00Europe/LondonCompound Library Generation using Flow ChemistryFlow Chemistry European Summit 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Pursuing new classes of compounds which can be used as new medicines for treatment of diseases is not a simple task. Researchers often create new active compounds from scratch, through a laborious process involving synthesizing and testing thousands of compounds aiming to find those suitable to be tested in human beings. In this context, Medicinal Chemistry is an interdisciplinary science at the interface of chemical biology, pharmacology, and medicine playing a fundamental role to define novel therapeutic approaches and discover new drugs. One of the major purposes of medicinal chemistry is the design and synthesis of new lead compounds for druggable targets. This process involves the synthesis and testing of often tens of thousands of exploratory compounds to disclose one new drug. From a medicinal chemist’s view point the synthesis of diverse compounds to screen is a key part of the drug discovery process. Chemists are constantly looking for alternative solutions to solve limitations of chemical synthesis, to increase the tools in their toolbox. The adoption of enabling chemical technologies as automation and flow systems have enabled chemists to shorten iterative learning cycles through early discovery to production and to the point of care.
The content of the presentation will cover a range of topic areas around how flow chemistry impacts and enables the generation of new, diverse compound libraries through the use of automated flow chemistry techniques to accelerate the early drug discovery process. While chemists at each stage of the drug discovery and development process will see specific benefits when implementing continuous flow techniques, the pharmaceutical industry’s desire to ultimately move towards the continuous manufacturing of future drugs means all stages of the drug lifecycle need to be aware of – and potentially implementing – continuous flow.
Add to Calendar ▼2024-03-25 00:00:002024-03-26 00:00:00Europe/LondonFlow Chemistry European Summit 2024Flow Chemistry European Summit 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2024-03-25 16:30:002024-03-25 17:30:00Europe/LondonCompound Library Generation using Flow ChemistryFlow Chemistry European Summit 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
